How to Get Jatenzo in Delaware

Jatenzo Basics: What Makes It Different from Injectable TRT

Jatenzo is the only FDA-approved oral testosterone undecanoate capsule for adult men with hypogonadism. The FDA approved it in March 2019 as an alternative to injectable and topical testosterone formulations. It bypasses first-pass liver metabolism through lymphatic absorption when taken with food, which is why the label specifies dosing with a meal containing at least 15 g of fat.

In the key registration trial by Swerdloff et al. (2020, N=166), 87% of men on 237 mg twice daily achieved a mean 24-hour testosterone concentration within the eugonadal range (300 to 1 to 100 ng/dL) by day 90. The starting dose is 237 mg taken twice daily. Clinicians titrate to 158 mg or 396 mg based on a serum testosterone level drawn 6 hours post-dose after roughly one month of therapy [1].

Oral dosing eliminates the need for injections or transdermal gels that risk skin-to-skin transfer. For Delaware patients who prefer a non-injectable option, or those who have experienced injection-site reactions, Jatenzo fills a gap that other testosterone formulations do not.

Who Can Prescribe Jatenzo in Delaware

Any Delaware-licensed prescriber with authority to prescribe Schedule III controlled substances can write a Jatenzo prescription. This group includes physicians (MDs and DOs), nurse practitioners (APRNs), and physician assistants (PAs) operating under Delaware's collaborative agreement rules.

Delaware APRNs have had full prescriptive authority, including Schedule II through V substances, since the state's 2015 scope-of-practice update. PAs may prescribe Jatenzo under a supervising physician delegation agreement that explicitly includes controlled substances. For straightforward male hypogonadism cases, primary care providers often initiate therapy. Complex cases (pituitary pathology, fertility preservation concerns, prior cardiovascular events) typically warrant referral to an endocrinologist or urologist.

The Endocrine Society's 2018 Clinical Practice Guideline recommends that testosterone therapy be prescribed by clinicians who can monitor hematocrit, PSA, lipids, and blood pressure at regular intervals [2]. Delaware has no state-specific restriction beyond the standard DEA licensure and state controlled-substance registration.

How Delaware Telehealth Laws Apply to Jatenzo

Delaware permits telehealth prescribing of Schedule III controlled substances under Title 24, Chapter 17 of the Delaware Code. This means a clinician licensed in Delaware can evaluate a patient via synchronous video visit, order labs electronically, and prescribe Jatenzo without an in-person encounter, provided the standard of care for hypogonadism diagnosis is met.

Two morning testosterone draws remain required before prescribing. Telehealth platforms typically direct patients to a local Quest Diagnostics, LabCorp, or hospital outpatient lab for blood work. Delaware has 14 Quest Diagnostics and 9 LabCorp patient service centers across New Castle, Kent, and Sussex counties, so access is not a bottleneck even in southern Delaware.

The American Urological Association (AUA) guidelines affirm that the diagnosis of hypogonadism requires at least two early-morning serum total testosterone measurements below 300 ng/dL, confirmed by a reliable assay [3]. A telehealth clinician reviewing these results remotely is held to the same diagnostic threshold as one in a brick-and-mortar clinic.

Patients should confirm that the telehealth platform they choose is staffed by providers who hold active Delaware medical licenses. Out-of-state providers cannot prescribe controlled substances to Delaware residents unless they also carry a Delaware license and DEA registration linked to a Delaware address.

Required Labs Before Starting Jatenzo in Delaware

Lab work is not optional. The following panel is standard before a clinician will write a Jatenzo prescription, and most insurers in Delaware require these results to approve a prior authorization request:

Mandatory baseline labs:

• Two morning total testosterone levels (drawn before 10 AM, on separate days)
• Complete blood count (CBC) with hematocrit
• Comprehensive metabolic panel (CMP), including hepatic function
• Lipid panel (LDL, HDL, triglycerides)
• PSA (prostate-specific antigen) for men aged 40 and older

Recommended but not always required:

• Free testosterone (equilibrium dialysis preferred)
• LH and FSH (to distinguish primary from secondary hypogonadism)
• Prolactin (if total testosterone is below 150 ng/dL)
• Estradiol
• SHBG (sex hormone-binding globulin)

The Endocrine Society guideline [2] specifies that hematocrit must be below 50% at baseline before initiating testosterone. A hematocrit above 54% during treatment triggers dose reduction or temporary cessation. Swerdloff et al. reported that mean hematocrit increased by 2.8 percentage points over 12 months in the Jatenzo arm, with 3.6% of subjects exceeding 54% [1]. Monitoring CBC at 3, 6, and 12 months, then annually, is the standard follow-up schedule.

Blood pressure monitoring is also written into the Jatenzo label. The FDA noted a dose-dependent increase in systolic blood pressure of approximately 3 to 5 mmHg compared to topical testosterone in post-marketing safety analyses [4]. Delaware clinicians are expected to assess cardiovascular risk factors before prescribing.

Delaware Medicaid and Insurance Coverage for Jatenzo

Delaware Medicaid covers Jatenzo for the indication of male hypogonadism, but a prior authorization (PA) is required. The PA process verifies that:

1. The patient has a documented diagnosis of hypogonadism (ICD-10 E29.1)
2. Two morning serum total testosterone values are below 300 ng/dL
3. The prescriber has assessed cardiovascular risk
4. The patient has either failed or has a documented contraindication to at least one generic testosterone formulation (this step varies by plan)

Private insurers in Delaware (Highmark BCBS Delaware, Aetna, Cigna) follow similar PA criteria. Step therapy is common. Many plans require a trial of generic testosterone cypionate injections or generic topical testosterone before approving a brand-name oral capsule. The average wholesale price (AWP) for Jatenzo runs approximately $650 to $750 for a 30-day supply, which is the primary reason payers enforce step therapy [5].

Tolmar offers a manufacturer copay card that can reduce out-of-pocket costs to as low as $0 for commercially insured patients, with a maximum annual benefit that varies by program year. Patients on government insurance (Medicaid, Medicare, TRICARE) are not eligible for manufacturer copay assistance per federal anti-kickback statute rules.

For patients paying cash, GoodRx and similar discount platforms show Delaware pharmacy prices for Jatenzo ranging from $500 to $900 per month depending on the pharmacy. Specialty pharmacies and mail-order pharmacies sometimes offer lower pricing than retail chains.

Prior Authorization Documentation for Delaware Plans

The PA submission package for Jatenzo in Delaware should include these specific elements:

• Prescription: Jatenzo (testosterone undecanoate) 237 mg capsules, #120 (60-day supply), Sig: one capsule by mouth twice daily with food
• Lab results: two morning total testosterone values with dates, lab name, and reference range
• CBC: baseline hematocrit value
• Diagnosis code: E29.1 (testicular hypofunction)
• Clinical notes: brief statement of symptoms (fatigue, decreased libido, erectile dysfunction, loss of lean mass)
• Step therapy documentation: if the plan requires prior trial of another testosterone formulation, include dates of prior therapy and reason for discontinuation (injection phobia, skin transfer risk, injection-site reaction, hematocrit elevation on injectable formulation)

Most Delaware payers process PA requests within 48 to 72 hours. If denied, a peer-to-peer review with the plan's medical director is the standard next step. The approval period is typically 6 to 12 months, after which re-authorization with updated labs is required.

Pharmacy Access: Filling Jatenzo in Delaware

Jatenzo is available at retail chain pharmacies (CVS, Walgreens, Rite Aid) and specialty pharmacies in Delaware. Because it is a Schedule III controlled substance, the prescription cannot be called in by phone. It must be transmitted electronically (e-prescribe) or presented as a written prescription with a wet signature.

Delaware allows up to five refills on a Schedule III prescription within six months of the date written, per 21 CFR 1306.22 and Delaware Uniform Controlled Substances Act guidelines. A 90-day supply requires the prescriber to write the quantity accordingly and the insurer to authorize the fill duration.

Stock availability can be inconsistent at lower-volume pharmacies. Patients should call ahead to confirm the pharmacy carries Jatenzo or can order it within 1 to 3 business days. Specialty pharmacies affiliated with telehealth platforms often pre-stock Jatenzo and can ship directly to the patient's Delaware address.

503A Compounding Pharmacies and Oral Testosterone in Delaware

Licensed 503A compounding pharmacies can prepare oral testosterone undecanoate capsules for Delaware patients with a valid patient-specific prescription. A 503A pharmacy compounds medications for an individual patient based on a prescriber's order, which is different from a 503B outsourcing facility that produces larger batches without patient-specific prescriptions.

Delaware's Board of Pharmacy permits 503A pharmacies to ship compounded preparations to patients within the state. Out-of-state 503A pharmacies may also ship into Delaware if they hold a Delaware non-resident pharmacy license.

The compounded version of oral testosterone undecanoate is not bioequivalent to brand-name Jatenzo. Jatenzo uses a proprietary self-emulsifying drug delivery system (SEDDS) technology that optimizes lymphatic absorption [1]. A compounded capsule may use different excipients and produce different pharmacokinetics. Patients considering a compounded alternative should discuss bioavailability differences with their prescriber.

Compounded oral testosterone undecanoate typically costs $100 to $250 per month, significantly less than brand Jatenzo. The trade-off is less predictable absorption and no FDA-reviewed safety or efficacy data specific to the compounded formulation.

Transferring a Jatenzo Prescription to a Delaware Pharmacy

Patients relocating to Delaware can transfer an existing Jatenzo prescription from an out-of-state pharmacy. Schedule III transfers are permitted under federal regulation (21 CFR 1306.26), and Delaware does not impose additional restrictions beyond the federal rule.

The receiving Delaware pharmacy contacts the originating pharmacy to verify the prescription, remaining refills, and dispensing history. Only one transfer is allowed per prescription under federal law. If the original prescription has no remaining refills, a new prescription from a Delaware-licensed (or DEA-registered with Delaware address) provider is required.

Telehealth platforms simplify this process. A patient can schedule a video visit with a Delaware-licensed clinician, present prior lab work and medical records, and receive a new e-prescription sent directly to a Delaware pharmacy. The entire process, from visit scheduling to pharmacy receipt of the prescription, can take as few as 3 to 5 business days.

Timeline: From First Visit to First Dose in Delaware

Here is a realistic timeline for a Delaware patient starting from scratch:

• Days 1 to 3: Schedule telehealth or in-person visit; complete first morning testosterone draw
• Days 4 to 7: Complete second morning testosterone draw (must be a separate day from the first)
• Days 7 to 10: Lab results returned; clinician reviews and confirms hypogonadism diagnosis
• Days 10 to 12: Prescription written and submitted to pharmacy; PA submitted to insurer if needed
• Days 12 to 17: PA decision returned (48 to 72 hours typical); pharmacy fills prescription
• Day 14 to 21: Patient picks up or receives shipped Jatenzo; begins 237 mg twice daily with food

Patients with recent labs (drawn within 90 days) and an established diagnosis can compress this timeline to 5 to 7 days. The bottleneck is almost always the prior authorization, not the clinical evaluation.

Monitoring After Starting Jatenzo in Delaware

Follow-up labs are scheduled at specific intervals. A serum testosterone level drawn 6 hours post-dose at the 1-month mark guides dose titration. The target is a total testosterone between 300 and 1 to 100 ng/dL at that time point.

The Endocrine Society recommends checking hematocrit at 3, 6, and 12 months during the first year, then annually [2]. PSA and a digital rectal exam (for men over 40) should occur at 3 to 6 months after initiation and then per age-appropriate screening guidelines. Lipid panels are rechecked at 6 to 12 months.

Blood pressure should be measured at every follow-up. The Jatenzo label carries a boxed warning about the potential for blood pressure increases, and the FDA advisory committee review documented that 7.8% of Jatenzo-treated patients in the registration trial developed new-onset hypertension versus 3.9% in the topical testosterone comparator arm [4]. Patients with pre-existing hypertension need closer surveillance: home blood pressure logs reviewed at each telehealth or office visit are a practical approach.

Delaware telehealth platforms can manage all follow-up monitoring remotely. Lab orders are sent electronically, results are reviewed asynchronously or during a video visit, and prescription adjustments are transmitted to the pharmacy without an in-person appointment.